BioSpace News Archive

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Singapore Health Sciences Authority (HSA) has approved the interim authorization of its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under the Pandemic Special Access Route (PSAR).

AACC is pleased to announce that, as of January 22, it has sold Lab Tests Online—an award-winning public resource on laboratory testing—to the digital health company OneCare Media.

Scientists at the University of Denver have tested a new antibody test for COVID-19 that can predict if a patient will experience mild versus more severe symptoms of the virus.

The report was issued by Anthony Nieves, CPSM, C.P.M., A.P.P., CFPM, Chair of the Institute for Supply Management® Services Business Survey Committee: “The Services PMI® registered 58.7 percent, 1 percentage point higher than the seasonally adjusted December reading of 57.7 percent.

Bion Environmental Technologies, Inc. (OTC QB: BNET), a developer of patented waste treatment technology incorporated within a business model focused on the production of branded sustainable livestock products in the beef, pork, and other sectors, announced it has concluded the core optimization testing of its third generation (3G) technology platform.

Phylloceuticals, a privately-held, global technology company dedicated to providing medicine to underserved areas of the world, announced its formation today.

iSpecimen today announced it has expanded its cellular biospecimen offerings by introducing new cryopreserved stem and immune cell products for life science research and preclinical drug development.

Positive Preclinical Data to be Submitted for Presentation or Publication in 1H 2021; Lead NK Cell Candidate On Track to Begin Clinic Trials in 2H 2021

- Today, ams (SIX: AMS), a leading worldwide supplier of high-performance sensor solutions, announces that it has chosen the high-performance cloud infrastructure developed by Extra Horizon to power a range of innovative point-of-care, spectral sensor-based solutions that harness the full power of digital health.

CytoImmune Therapeutics and Biosimilar Sciences US will soon call Puerto Rico home and engage in cancer immunotherapy solutions and a COVID-19 vaccine, respectively